John D Quisel

CEO John D Quisel sold 34,000 shares ($2.4M) via 10b5-1 plan; holds 226,064 shares post-trade plus 41,375 stock options.

John D Quisel, Chief Executive Officer of Disc Medicine, executed three separate sales totaling 34,000 shares for $2,387,295.70 at an average price of $70.21, reducing his non-derivative holdings from 260,064 to 226,064 shares (-13.1%). The sales were conducted under a 10b5-1 trading plan adopted on 2026-03-12, meaning the transactions were scheduled and pre-arranged rather than discretionary decisions. Quisel retains 41,375 stock options and significant non-derivative holdings, so this represents a partial rebalancing of his equity stake. The company reported a full-year net loss of $-63,504,000, which is material context for executive equity activity; however, the stock has appreciated 5.4% over 30 days and 12.6% over 90 days, currently trading at $70.45 relative to a 52-week high of $99.50. The 10b5-1 framework establishes these sales as pre-committed executions rather than timing-dependent signals, limiting inference about current management confidence levels.

CEO Quisel John D sold 13,264 shares of IRON at $62.86 on 2026-02-17; stock down -30.3% from 52-week high.

Quisel John D, Chief Executive Officer of Disc Medicine, reduced his position by 13,264 shares (5.5% of pre-transaction holdings) at $62.86, leaving him with 226,064 shares. The sale occurs as IRON trades -30.3% below its 52-week high and -7.6% over the prior 30 days, with the company unprofitable at $-62,321,000 net income for its most recent fiscal year. His prior four sales at this same ticker (all on 2025-12-11) have produced declines of -14.1% to -16.6% over their subsequent 30-day windows, though only one prior 90-day outcome is measurable at this ticker (the 2025-07-09 sale, which showed +22.9%, poorly timed). Across all his open-market history and all tickers, his cross-ticker track record shows an 81.82% well-timed rate on 15 prior sells with an average 90-day return of -11.8%, suggesting a pattern of selling before stock declines. The timing of this sale relative to recent and sustained price weakness deserves scrutiny given the company's unprofitability and the CEO's recent concentrated selling activity at this same security.

CEO Quisel sells 40,000 IRON shares for $3.7M at $93.05 blended price; company posted $-62.3M net loss

Quisel John D, Chief Executive Officer of Disc Medicine, executed 4 separate sales totaling 40,000 shares for $3,721,931.19 on 2025-12-11, reducing his holdings by 18.9% from 211,828 to 171,828 shares. The sales occurred at prices ranging from $90.97 to $93.65 per share, slightly above the current price of $92.00 and near the 52-week high of $94.11. The company reported a net loss of $-62,321,000.00 in its most recent full fiscal year, indicating ongoing profitability challenges. While his prior sales at IRON show mixed timing patterns (3 of 5 well-timed at 90 days), this large concentration of sales by the CEO during a period when the company remains unprofitable warrants investor attention to any forward guidance or structural improvements management may communicate.

CEO John D Quisel sells 34.8K shares for $1.9M at blended $55.33; 5 of 5 prior IRON sells well-timed, company posted -$34.1M net income

CEO John D Quisel executed 2 separate sales totaling 34,800 shares for $1,925,524.86 at blended average price $55.33, reducing his holdings from 196,628 shares to 161,828 shares. His prior trades at IRON show a consistent pattern: all 5 prior sells on this ticker were well-timed at the 90-day mark, with 90-day returns ranging from -15.4% to -18.1%, indicating the stock declined each time after he sold. The company is unprofitable, having posted net income of -$34,085,000 over its most recent full fiscal year. This filing warrants close attention to whether the latest sales follow the established pattern and whether future fundamental developments validate or contradict the timing signal embedded in his prior IRON trade history.

Disc Medicine CEO John D Quisel sells 13,012 shares for $806,057.55 on 2024-12-30, reducing stake by -13.7%

CEO John D Quisel executed 2 separate sales totaling 13,012 shares for $806,057.55 on 2024-12-30 at blended average price of $61.95, reducing his holdings from 95,077 shares to 82,065 shares. The sale follows 5 prior trades at IRON within the past two weeks (multiple sells on 2024-12-23 and 2024-12-16), establishing a pattern of consecutive liquidation activity by the company's top executive during a period when stock has risen 25.1% over 90 days but declined 3.5% over 30 days and sits 17.1% below its 52-week high. Notably, the company is currently unprofitable with net income of $-26,599,000.00 over its most recent full fiscal year, presenting a context of operational challenges against which the CEO's sustained selling activity warrants investor attention.

CEO Quisel sold 19,820 shares in 3 separate transactions for $1,251,357.22, retaining 72,065 shares post-sale.

Quisel John D, CEO of Disc Medicine, executed three separate stock sales on 2024-12-23, totaling 19,820 shares (19.8K shares) at prices ranging from $62.38 to $63.80 and yielding $1,251,357.22 ($1.3M). He retains 72,065 shares (72.1K shares) after the sales, representing a 21.6% reduction in his prior holdings of 91,885 shares. The timing is notable: the stock is currently at $65.54, only 13.0% below its 52-week high of $75.32, having appreciated 4.6% over 30 days and 30.9% over 90 days. The company reported negative net income of $-26,599,000.00 ($-26.6M) in its most recent full fiscal year, indicating unprofitable operations. The CEO's prior four trades at IRON were all sells on 2024-12-16 (outcomes not yet measurable), suggesting a pattern of recent dispositions, though the cross-ticker track record shows only 4 prior sells across all holdings.

CEO Quisel sells 12,791 shares for $844,314.09 as IRON stock rallies +30.7% in 90 days despite -$26.6M net loss

Quisel John D, CEO of Disc Medicine, executed 4 separate sales totaling 12,791 shares for $844,314.09 on 2024-12-16, reducing his holdings by 15.1% from 84,856 shares to 72,065 shares post-transaction. The blended average sale price of $66.01 sits above the current price of $63.50, and notably above the 52-week low of $26.52, reflecting a period of sustained stock appreciation of +30.7% over the prior 90 days. This large insider sale by the company's chief executive occurs in the context of significant operational headwinds: the company posted a full-year net income of -$26,599,000, indicating substantial unprofitability. The scale of the sale—12.8K shares—combined with the company's negative earnings profile and the stock's recent run-up, frames this as a material reduction in CEO ownership at a point of elevated valuation relative to operational performance.